000			04248nam a22004335i 4500
999			_c383727 _d383727
001			383727
003			ES-MaUEC
005			20230102122144.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			201208s2021 sz | s |||| 0|eng d
020			_a9783030562670
024	7		_a10.1007/978-3-030-56267-0 _2doi
040			_bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC271 .R3 _b2021 EB
245	0	0	_aLocoregional Radionuclide Cancer Therapy : _bClinical and Scientific Aspects _cedited by Franklin C.L. Wong
250			_a1st edition 2021
264		1	_aCham _bSpringer International Publishing _c2021
300			_a1 recurso en línea (XII, 268 páginas) _b76 ilustraciones, 56 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aarchivo de texto _bPDF
505	0		_aHuman Cancer- Epidemiology, Hallmarks, and Defense Strategies -- Cancer Treatment Modalities Systemic and Loco regional Approaches: Challenges and Opportunities of multidisciplinary approaches -- Cancer Radiotherapy: General Considerations and Human Radiobiology -- Radionuclide Cancer Therapy- Unsealed Alpha, Beta and Gamma Emitters -- Locoregional Therapy - Cancer Interventions with and without Radionuclides -- Radiation Dosimetry Considerations of Locoregional Radionuclide Cancer Therapy -- Voxel-based Targeted Radionuclide Therapy Dosimetry -- Locoregional Unsealed Radionuclide Cancer Therapy - Experimental Findings -- Animal Cancer Therapy Models - Ready Translation to Humans -- An Overview of Regulations of Radiopharmaceuticals -- Locoregional Radionuclide Cancer Therapy (LRCT) Using Sealed & Unsealed Radionuclides.
520	3		_aThis book reviews locoregional radionuclide cancer therapies (LRCT). Proving an increasingly viable alternative to radiotherapy, radionuclide therapy includes a diversity of choices of well characterized biochemical and physiologic target molecules. The delivery and retention of radionuclides may be monitored by advanced imaging for exact tissue localization and for real-time dosimetry to enable personalized precision medicine. Radiopharmaceuticals in human cancer therapies are typically delivered in systemic routes but can also be designed for locoregional routes to harness pharmacokinetic advantages of higher payload and lower systemic toxicities. This book explores the latest advancements and clinical considerations of the locoregional approach. Throughout the chapters, the clinical and scientific bases of cancer treatment and the locoregional use of radionculides are explored. Mathematical models of radiation dosimetry of locoregional radionculdies on tissues are studied using common models for multiple commercially available radionuclides. Rodent and canine tumor models of LRCT are compared for selected radionuclides and radiopharmaceuticals. The practical aspects of radiopharmaceuticals production, marketing, transport, as well as radiation protection are reviewed. Finally, the combination of LRCT with immunotherapy and other cancer therapies and prospective future use of LRCT are discussed. This is a guide for practicing nuclear physicians, interventional radiologists, radiation oncologists, radiation scientists, veterinarians and oncologists to expand their knowledge base and to prepare for designing locoregional radionuclide cancer therapies in animals and in humans.
988			_aSpringer_Medicine_2021
650		7	_2embne _9141446 _aProductos radiofarmacéuticos
650		7	_2embne _9186645 _aCáncer _xRadioterapia
650		7	_2embne _9138396 _aMedicina nuclear
700	1		_aWong, Franklin C. L. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030562663
776	0	8	_iPrinted edition: _z9783030562687
776	0	8	_iPrinted edition: _z9783030562694
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-56267-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b11/2022 _dz _eu _zSI